Differentiation therapy for myeloid malignancies: beyond cytotoxicity
Abstract Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens promoting differentiation have resulted in incredible cure rates in certain AML subtypes, such as acute promyeloc...
Guardado en:
Autores principales: | Ryan J. Stubbins, Aly Karsan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/64c595335162450d8bb5ecde6e432f98 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Malignant retroperitoneal fibrosis in lung adenocarcinoma
por: Natalie Uy, et al.
Publicado: (2021) -
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Jean Galtier, et al.
Publicado: (2021) -
Endothelial cell malignancies: new insights from the laboratory and clinic
por: Michael J. Wagner, et al.
Publicado: (2017) -
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda K, et al.
Publicado: (2013) -
Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
por: Sumanth Nagabushan, et al.
Publicado: (2021)